NASDAQ:CNSP - Nasdaq - US18978H4092 - Common Stock - Currency: USD
NASDAQ:CNSP (4/28/2025, 11:31:07 AM)
1.07
-0.02 (-1.83%)
The current stock price of CNSP is 1.07 USD. In the past month the price decreased by -17.42%. In the past year, price decreased by -99.8%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 66.9 | 824.50B | ||
JNJ | JOHNSON & JOHNSON | 15.44 | 373.91B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.2 | 278.77B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.23 | 223.15B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17 | 218.70B | ||
MRK | MERCK & CO. INC. | 10.7 | 209.82B | ||
PFE | PFIZER INC | 7.42 | 130.84B | ||
SNY | SANOFI-ADR | 13.75 | 129.58B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.58B | ||
GSK | GSK PLC-SPON ADR | 8.74 | 77.05B | ||
ZTS | ZOETIS INC | 25.99 | 68.63B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.96 | 47.71B |
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
CNS PHARMACEUTICALS INC
2100 West Loop S Ste 900
Houston TEXAS 77027 US
CEO: John Climaco
Employees: 4
Company Website: https://cnspharma.com/
Investor Relations: https://ir.cnspharma.com/
Phone: 18009469185
The current stock price of CNSP is 1.07 USD. The price decreased by -1.83% in the last trading session.
The exchange symbol of CNS PHARMACEUTICALS INC is CNSP and it is listed on the Nasdaq exchange.
CNSP stock is listed on the Nasdaq exchange.
8 analysts have analysed CNSP and the average price target is 204 USD. This implies a price increase of 18965.42% is expected in the next year compared to the current price of 1.07. Check the CNS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CNS PHARMACEUTICALS INC (CNSP) has a market capitalization of 3.15M USD. This makes CNSP a Nano Cap stock.
CNS PHARMACEUTICALS INC (CNSP) currently has 4 employees.
CNS PHARMACEUTICALS INC (CNSP) has a resistance level at 1.1. Check the full technical report for a detailed analysis of CNSP support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CNSP does not pay a dividend.
CNS PHARMACEUTICALS INC (CNSP) will report earnings on 2025-05-13.
CNS PHARMACEUTICALS INC (CNSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-810).
The outstanding short interest for CNS PHARMACEUTICALS INC (CNSP) is 11.56% of its float. Check the ownership tab for more information on the CNSP short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CNSP. While CNSP seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CNSP reported a non-GAAP Earnings per Share(EPS) of -810. The EPS increased by 5.26% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -170.76% | ||
ROE | -240.55% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 80% to CNSP. The Buy consensus is the average rating of analysts ratings from 8 analysts.